Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 12/20 | 0.40 |
| ▸ | GRIN2D | O15399 | 4/20 | 0.37 |
| ▸ | GRIN3B | O60391 | 4/20 | 0.37 |
| ▸ | GRIN1 | Q05586 | 4/20 | 0.37 |
| ▸ | GRIN2A | Q12879 | 4/20 | 0.37 |
| ▸ | GRIN2B | Q13224 | 4/20 | 0.37 |
| ▸ | GRIN2C | Q14957 | 4/20 | 0.37 |
| ▸ | GRIN3A | Q8TCU5 | 4/20 | 0.37 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CETP | P11597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28105514 | 0.79 | CYP2D6 (0.61) | SIGMAR1OPRL1ALDH1A1CYP2D6 | |
| SCHEMBL27750414 | 0.77 | HPGD (0.38) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1531618 | 0.76 | CYP1A2 (0.51) | OPRL1ALDH1A1CYP2D6P2RX7CYP1A2 | |
| SCHEMBL2542108 | 0.75 | CYP1A2 (0.50) | OPRL1ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL3407690 | 0.73 | CYP1A2 (0.49) | SIGMAR1OPRL1P2RX7CYP1A2 | |
| SCHEMBL3410176 | 0.70 | DPP4 (0.38) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL2148591 | 0.69 | SIGMAR1 (0.56) | SIGMAR1GRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL1531517 | 0.68 | CA12 (0.51) | ALDH1A1CYP2D6CYP1A2 | |
| SCHEMBL6981631 | 0.68 | OPRL1 (0.40) | SIGMAR1OPRL1ALDH1A1CYP2D6P2RX7 | |
| SCHEMBL3404013 | 0.67 | CETP (0.35) | ALDH1A1CETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2197838-B1 | NOVEL PHENYLUREA DERIVATIVES, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-8394990-B2 | Phenylurea inhibitors of the enzyme SOAT-1 and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-03-12 | — | — | US | disclosed |
| US-20100197735-A1 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-05 | — | — | US | disclosed |
| EP-2197838-A1 | NOVEL PHENYLUREA DERIVATIVES, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | Galderma Research & Development (FR) | 2010-06-23 | — | — | EP | disclosed |
| WO-2009030746-A1 | NOVEL PHENYLUREA DERIVATIVES, INHIBITORS OF THE ENZYME SOAT-1, AND PHARMACEUTICAL AND COSMETIC COMPOSITIONS CONTAINING THEM | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-03-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197735-A1 | NOVEL PHENYLUREA INHIBITORS OF THE ENZYME SOAT-1 AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF | SOAT1, SOAT2, ACAT2 | SIGMAR1 1334/4885GRIN2D 4802/4885GRIN3B 4675/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.